In summary, we have demonstrated that DZNep selectively inhibits BRCA1-deficient but not BRCA1-proficient mammary tumor cells, and that this effect is mainly due to the fact that BRCA1-deficient cells are dependent on EZH2, whereas BRCA1-proficient cells are not. This evidence concerns the gene BRCA1 and breast cancer.